Two weeks ago we discussed
Vanda argued that the Court should instead adopt a "predictable results" standard, which would have made patents more difficult to challenge and thereby significantly impacted the pharma and biologics industries. Unsurprisingly, the Court today denied Vanda's petition, leaving the obviousness standard unchanged.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
NY 10036
Tel: 212728 2200
Fax: 212728 2201
E-mail: jchodos@axinn.com
URL: www.axinn.com
© Mondaq Ltd, 2024 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source